Camurus Ab (CAMRF) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you, Einar, and hello, everyone. Welcome to our second quarter earnings call. Here are our forward-looking statements. So the agenda for our call today is a summary of highlights in the quarter, followed by financial and commercial performance reviews, then an update on the pipeline and business development before finishing off with Q&A. So with me to provide the financial update is John Garay, CFO, Also present are Richard Jameson, Chief Commercial Officer, and Anders Walshorp, incoming CFO. Camurus had a successful second quarter with good performances across our business. Financially, we delivered all-time record revenues, high profitability, further strengthening our cash position for planned expansions and pipeline investments. And on the corporate side, we entered a strategically important license agreement for long-acting incretins with Eli Lilly, as you know, a world leader in cardiometabolic disease. Commercially, our teams continued execution with Bovidal growing in Europe and the rest of the world, Brixhadi regaining momentum after a quiet first quarter, and in the R&D pipeline, key milestones were achieved. Of course, the EU approval of Oxisa for the treatment of Acromegaly was a clear highlight, which is now the first of a new generation products based on our innovative fluid crystal technology. We also received positive results from the Positano study and also the AcroInnova extension trials. So with this notable progress, I hand over to John for actually his final review of our financial performance. So here, John. Yes, indeed, Frederik. Thanks a lot, Frederik, and good afternoon, everyone. Camurus delivered strong financial performance in Q2, and I would like to share now the main highlights. Camurus achieved 676 million SEK total revenue in the...